Opinion

Why Eli Lilly Stock Slumped Today

Investors worried that the company could take quite a revenue hit due to a competitor's move.
Novo Nordisk just did Eli Lilly stock a huge favor.
Novo Nordisk shares fell following the news that the drug maker plans to slash its U.S. list prices for its popular obesity ...
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.8% in the afternoon session after a major competitor, Novo Nordisk, announced that its experimental obesity drug ...
Novo’s CagriSema shot was shown to be less effective than rival Lilly’s tirzepatide ...
Novo shares slump after the Danish drugmaker’s experimental obesity drug fails to beat Lilly’s treatment in an 84-week trial.
Eli Lilly has long been gearing up for the launch of orforglipron, announcing as early as February 2024 that it was ramping ...
This one-day decline has now brought NVO’s twelve-month return to -56%. The pertinent question: Is this a buying opportunity?
Novo Nordisk stock fell over 16% Monday after it said its next-generation weight loss drug didn't meet its primary target.